{"filing":{"accession_number":"0001193125-26-328784","cik":"0001662774","ticker":"QNCX","company_name":"Quince Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-31","report_date":"2026-07-29","primary_document":"d160394d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526328784/d160394d8k.htm"},"events":[{"id":22456,"run_id":20314,"accession_number":"0001193125-26-328784","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"The filing discloses conditional appointments of three key executives—Brigette Roberts as CEO, John Militello as CFO, and Keith Fandrick as COO—effective upon stockholder approval of acquisition-related proposals at the September 25, 2026 Special Meeting. While the section also mentions conditional resignations of the current CEO and COO, the Board's affirmative action on July 29, 2026 was to approve these three appointments, making the appointment the principal disclosed action. The appointments are material as they represent a complete change in the executive leadership team contingent on stockholder approval of the Orphai acquisition.","company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","filing_date":"2026-07-31","form":"8-K","submitted_at":null,"items":[{"id":22400,"accession_number":"0001193125-26-328784","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses conditional appointments of three key executives—Brigette Roberts as CEO, John Militello as CFO, and Keith Fandrick as COO—effective upon stockholder approval of acquisition-related proposals at the September 25, 2026 Special Meeting. While the section also mentions conditional resignations of the current CEO and COO, the Board's affirmative action on July 29, 2026 was to approve these three appointments, making the appointment the principal disclosed action. The appointments are material as they represent a complete change in the executive leadership team contingent on stockholder approval of the Orphai acquisition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-01T00:22:16.700672+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":22400,"accession_number":"0001193125-26-328784","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses conditional appointments of three key executives—Brigette Roberts as CEO, John Militello as CFO, and Keith Fandrick as COO—effective upon stockholder approval of acquisition-related proposals at the September 25, 2026 Special Meeting. While the section also mentions conditional resignations of the current CEO and COO, the Board's affirmative action on July 29, 2026 was to approve these three appointments, making the appointment the principal disclosed action. The appointments are material as they represent a complete change in the executive leadership team contingent on stockholder approval of the Orphai acquisition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-01T00:22:16.700672+00:00","company_name":"Quince Therapeutics, Inc.","ticker":"QNCX","filing_date":"2026-07-31"}]}